Substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl) benzamides useful for the treatment of allergic diseases

A method of treating a condition selected from emesis, inflammatory bowel disease and uveitis in a patient in need thereof which comprises administering to said patient an antihistamic or NKI antagonistic effective amount of a compound of the following formula:

• wherein
• R′ is from 1 to 3 substituents each independently chosen from the group consisting of hydrogen, halogen, C1—C6 alkyl, and C1-C6 alkoxy;
• R″ is hydrogen or a radical chosen from the group consisting of
• wherein
• R20 is selected from the group consisting of hydrogen, C1-C4 alkyl, and —CF3;
• Ar1 is a radical chosen from the group consisting of
• wherein
• R1 is from 1 to 3 substituents each independently chosen from the group consisting of hydrogen, halogen, hydroxy, —CF3, C1-C6 alkyl, and C1-C6 alkoxy;
• R2 is from 1 to 2 substituents each independently chosen from the group consisting of hydrogen, halogen, C1-C6 alkyl, and C1-C6 alkoxy;
• X1 and X2 are as defined in one of parts A), B), or C):
• A) X1 is hydrogen;
• X2 is a radical chosen from the group consisting of
• wherein
• p is 1 or 2;
• R3 is from 1 to 3 substituents each independently chosen from the group consisting of hydrogen, halogen, —CF3, C1-C6 alkyl, and C1-C6 alkoxy;
• R4 is from 1 to 3 substituents each independently chosen from the group consisting of hydrogen, halogen, —CF3, C1-C6 alkyl, and C1-C6 alkoxy,
• R5 is hydrogen or hydroxy;
• Ar2 is a radical chosen from the group consisting of
• wherein
• R6 is from 1 to 3 substituents each independently chosen from the group consisting of hydrogen, halogen, —CF3, C1-C6 alkyl, C1-C6 alkoxy, and CO2R9 wherein R9 is chosen from the group consisting of hydrogen and C1 -C4 alkyl;
• R7 is from 1 to 2 substituents each independently chosen from the group consisting of hydrogen, halogen, C1-C6 alkyl, and C1-C6 alkoxy;
• R8 is chosen from the group consisting of hydrogen, —CH3, and —CH2OH;
• R10 is chosen from the group consisting of hydrogen, C1-C4 alkyl, and benzyl;
• Z is chosen from the group consisting of hydrogen, C1-C6 alkyl, —(CH2)w—O—(CH2)t—Y, —(CH2)fA, —(CH2)uCO2R11, —(CH2)uC(O)NR12R13, —(CH2)gC(O) (CH2)hCH3, —(CH2)w—O—Ar3, —CH2CH2OCF3, —CH2CF3, —CH2CH2CH2CF3, —(CH2)2CH═CH2, —CH2CH═CH2, —CH2CH═CHCH3, —CH2CH═CHCH2CH3, —CH2CH═C(CH3)2, and —CH2OCH2CH2Si(CH3)3
• wherein
• w is an integer from 2 to 5;
• t is an integer from 1 to 3;
• f is 2 or 3;
• u is an integer from 1 to 4;
• g is an integer from 1 to 3;
• h is an integer from 0 to 3;
• w is an integer from 2 to 4;
• Y is chosen from the group consisting of hydrogen, —CF, —CH═CH2, —CH═C(CH3)2, and —CO2R14 wherein R14 is chosen from the group consisting of hydrogen and C1-C4 alkyl;
• A is chosen from the group consisting of —NR15R16, acetylamino, and morpholino wherein R15 is chosen from the group consisting of hydrogen and C1-C4 alkyl and R16 is C1-C4 alkyl;
• R11 is chosen from the group consisting of hydrogen and C1-C4 alkyl;
• R12 is chosen from the group consisting of hydrogen, C1-C4 alkyl, and benzyl;
• R13 is chosen from the group consisting of hydrogen and C1-C4 alkyl;
• Ar3 is a radical chosen from the group consisting of
• wherein
• v is an integer from 1 to 3;
• R17 is chosen from the group consisting of hydrogen and —CO2R8 wherein R18 is chosen from the group consisting of hydrogen and C1-C4 alkyl;
• B) X1 is hydroxy;
• X2 is a radical chosen from the group consisting of
• wherein p, R3, Z, and Ar2 are as previously defined;
• C) X2 is a radical of the formula;
• wherein R3 and R4 are as previously defined;
• and
• X1 and Z1 taken together form a second bond between the carbon atoms bearing Xl and Z1;
• and stereoisomers and pharmaceutically acceptable salt thereof.